An observational study in Autism Spectrum Disorder (ASD), sponsored by Dr. Mehak Naeem. Not yet recruiting at 1 site in Pakistan. Open to participants aged 4 Years to 12 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Dr. Mehak Naeem · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies in Autism Spectrum Disorder with a site in Pakistan — 17 open to participants now, 21 under way, none of them phase 3. Autism Spectrum Disorder · Pakistan.
Among the 52 studies in Autism Spectrum Disorder with a site in Pakistan, this one is one of 13 that started in 2026, is one of 3 observational ones, reaches primary completion later than 14 of the 20 other live ones, and was the 43rd registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →17 of the 52 studies in Autism Spectrum Disorder with a site in Pakistan are open now. Recruiting first, the newest first:
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18+
Riphah International University · Sites in Pakistan
Ages 4–10
Riphah International University · Sites in Pakistan
Ages 6–12
Riphah International University · Sites in Pakistan
Ages 5–11
Riphah International University · Sites in Pakistan
Ages 8–12
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 4 Years to 12 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 13 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 36 across the 49 interventional studies, 200 across the 3 observational. Of the 29 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 52 has an industry lead sponsor. The 10 most frequent:
Dr. Mehak Naeem is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Dr. Mehak Naeem has 1 study filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
3 of the studies in Autism Spectrum Disorder with a site in Pakistan that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07911904Riphah International UniversitySIT and Deep Pressure Therapy Effects on Motor Coordination in Children With ASD | 2027-03-01 |
| NCT07722949Khyber Medical University PeshawarFeasibility of a Culturally Adapted Nurse-Led COPE Intervention for Caregivers of Children With Autism Spectrum Disorder | 2027-03-30 |
| NCT07921199Riphah International UniversitySensory-integration Therapy Verses Augumented Reality-based Training in ASD | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 52 studies in Autism Spectrum Disorder with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn if trunk control (the ability to balance and stabilize the upper body while sitting or moving) links autism severity to functional exercise capacity in children aged 4-12 years with Autism Spectrum Disorder (ASD). The main questions it aims to answer are:
Participants will complete two assessments in a single 30-40 minute session during their routine clinic visit:
No treatment or intervention is involved. All assessments are safe, non-invasive, and conducted at a tertiary care children's hospital in Pakistan.
Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by decreased cardiorespiratory fitness and motor impairments that limit participation in daily activities. Children with ASD commonly show reduced postural stability and trunk motor control (the ability to maintain and adjust the position of the upper body during movement). These impairments are increasingly recognized as significant contributors to functional limitations in individuals with ASD, yet the precise mechanism linking autism severity to reduced functional exercise capacity has not been formally tested.
This cross-sectional study tests a mediation model: whether trunk motor control explains the relationship between ASD severity and functional exercise capacity. ASD severity is classified using DSM-5 levels (Level 1, 2, and 3) from existing clinical records. Trunk motor control is assessed using the Trunk Impairment Scale (TIS), a validated tool measuring static balance, dynamic balance, and trunk coordination. Functional exercise capacity is measured using the Six-Minute Walk Test (6MWT), conducted per American Thoracic Society guidelines.
Statistical analysis uses bootstrap mediation (PROCESS Model 4, 5,000 resamples), controlling for age, sex, and BMI. This is the first study to examine this mediation pathway in a paediatric hospital setting in Pakistan, where no motor profile has been described in the literature for children with ASD.
Participants will be recruited consecutively from the developmental and rehabilitation paediatric physiotherapy outpatient department of a tertiary care children's hospital in Pakistan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children aged 4-12 years with a confirmed DSM-5 diagnosis of ASD at severity Level 1 (requiring support). Participants undergo a single assessment session comprising the Trunk Impairment Scale (TIS) to measure trunk motor control and the Six-Minute Walk Test (6MWT) to measure functional exercise capacity. No intervention is administered.
Children aged 4-12 years with a confirmed DSM-5 diagnosis of ASD at severity Level 2 (requiring substantial support). Participants undergo a single assessment session comprising the Trunk Impairment Scale (TIS) to measure trunk motor control and the Six-Minute Walk Test (6MWT) to measure functional exercise capacity. No intervention is administered.
Children aged 4-12 years with a confirmed DSM-5 diagnosis of ASD at severity Level 3 (requiring very substantial support). Participants undergo a single assessment session comprising the Trunk Impairment Scale (TIS) to measure trunk motor control and the Six-Minute Walk Test (6MWT) to measure functional exercise capacity. No intervention is administered.
Functional Exercise Capacity
Total distance covered in metres during the Six-Minute Walk Test (6MWT), administered in accordance with American Thoracic Society (ATS) guidelines along a 30-metre flat hospital corridor. The 6MWT is a validated, low-cost index of functional exercise capacity applicable to paediatric clinical settings. There is no fixed minimum or maximum value. A greater distance indicates better functional exercise capacity. Whereas a shorter distance indicates poorer functional exercise capacity. 6MWT distance will be analysed as a continuous variable and compared across DSM-5 severity levels.
Time frame: 1 Day
Trunk Motor Control
Total score on the Trunk Impairment Scale (TIS), a validated clinician-administered tool scored from 0 to 23 across three subscales: static sitting balance (0-7), dynamic sitting balance (0-10), and trunk coordination (0-6). Higher scores indicate better trunk motor control.
Time frame: 1 Day
Plan to share: Undecided — Individual participant data will not be shared, as the study involves a vulnerable paediatric population. Participant confidentiality and privacy are protected under the study's ethical approval conditions and applicable national research regulations of Pakistan.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Jul 2026, 1 month later.
Of 98 non-industry observational studies under Autism Spectrum Disorder, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 120. This study's planned 1 month is below that.
Counting every sponsor, half of 112 studies reached it within 40 months; a quarter within 26 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr. Mehak Naeem